경카테터 색전 및 폐색 기구 시장 규모, 점유율, 동향 분석 보고서 :제품별, 지역별, 부문별 예측(2025년-2030년)

Transcatheter Embolization And Occlusion Devices Market Size, Share & Trends Analysis Report By Product (Coil, Non-coil),By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,176,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,550,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,299,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

경카테터 색전 및 폐색 기구(TEO) 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 경 카테터 색전 및 폐색 장치 세계 시장 규모는 2025-2030년에 걸쳐 CAGR 7.7%로 성장할 것으로 예상되며, 2030년에는 85억 4,000만 달러에 달할 것으로 추정되고 있습니다.

TEO 장비 시장의 주요 촉진요인은 낮은 침습 수술의 채용 증가와 암 유병률의 상승을 포함합니다.

또, 혈관기형이나 섬유증 등, 암 이외의 질환의 치료로서 색전술이 널리 사용되고 있는 것이, 세계적으로 TEO 장치 수요를 촉진하고 있습니다. 또한, 효율을 높인, 기술적으로 선진적인 제품의 도입이 세상 세계 시장의 성장을 지원하고 있습니다. 한편, 고비용, 엄격한 규제 승인 절차, TEO 처치의 실시에는 경험 풍부한 의료 전문가가 필요한 것 등은 개발에 부정적인 영향을 줄 수 있는 요인의 하나입니다.

아시아태평양의 TEO 장비 시장은 의료 지출 증가와 의료 인프라의 개선으로 가장 높은 CAGR을 나타낼 전망입니다.

경카테터 색전 및 폐색 기구 시장 보고서 하이라이트

• 2024년에는 비코일 제품 부문이 52.3%의 최대 수익 점유율로 시장을 독점해, 그 다용도성과 폭넓은 임상 용도에서의 유효성에 뒷받침되었습니다.
• 코일 제품 부문은 다양한 혈관 질환의 치료에의 응용 확대에 의해 예측 기간 중에 CAGR 7.0%로 성장할 것으로 예상됩니다.
• 북미는 인터벤셔널 라디올로지(IR) 절차의 채택 증가로 2024년에 36.6%의 최대 수익 점유율로 세계 시장을 독점했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 경카테터 색전 및 폐색 기구 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 모 시장 전망
  • 관련/보조시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 경카테터 색전 및 폐색 기구 시장 분석 툴
  • 산업 분석 - Porter's Five Forces 분석
  • PESTLE 분석

제4장 경카테터 색전 및 폐색 기구 시장 : 제품별, 추정 및 동향 분석

• 제품 부문 대시보드
• 경카테터 색전 및 폐색 기구 시장 :제품 변동 분석
• 세계의 경카테터 색전 및 폐색 기구 시장 규모와 동향 분석(제품별, 2018-2030년)
• 코일
  • 압입 가능한 코일
  • 탈착식 코일
• 비코일
  • 유량 전환 장치
  • 색전 입자
  • 액체 색전
  • 기타 색전과 폐색 장치
  • 부속품

제5장 경카테터 색전 및 폐색 기구 시장 :지역별, 추정 및 동향 분석

• 지역별 시장 대시보드
• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 경카테터 색전 및 폐색 기구 시장 : 주요 포인트
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제6장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
• 기업/경쟁의 분류
• 벤더 상황
  • Key Company 히트맵 분석, 2024년
• 기업 프로파일
  • Boston Scientific Corporation
  • Terumo Corporation
  • Medtronic
  • DePuy Synthes(Johnson & Johnson)
  • Stryker
  • Cordis
  • Abbott
  • Pfizer Inc.
  • Sirtex SIR-Spheres Pty Ltd.
  • Nordion(캐나다) Inc.

SHW

영문 목차

영문목차

Transcatheter Embolization And Occlusion Devices Market Growth & Trends:

The global transcatheter embolization and occlusion devices market size is estimated to reach USD 8.54 billion by 2030, registering a CAGR of 7.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. Key drivers of the TEO devices market include increasing adoption of minimally invasive surgeries and rising prevalence of cancer.

In addition, wide usage of embolization technique as a treatment for conditions other than cancer, such as vascular malformations and fibrosis, is fueling the demand for TEO devices globally. Furthermore, introduction of technically advanced products with enhanced efficiency is supporting the global market growth. On the other hand, high cost, stringent regulatory approval procedures, and requirement of experienced healthcare professionals to perform TEO procedures are some of the factors that may have a negative impact on the market development.

Asia Pacific TEO devices market is anticipated to witness highest CAGR, due to increasing healthcare expenditure and improving healthcare infrastructure. Rapid expansion of medical tourism industry in the emerging countries of APAC is also boosting the demand for TEO devices.

Transcatheter Embolization And Occlusion Devices Market Report Highlights:

• In 2024, The non-coil product segment dominated the market with the largest revenue share of 52.3%, propelled by its versatility and effectiveness in a wide range of clinical applications.
• Based product, the coil segment is anticipated to grow at a significant CAGR of 7.0% over the forecast period, driven by its growing application in treating various vascular conditions.
• North America dominated the global market with the largest revenue share of 36.6% in 2024, attributed to the increased adoption of Interventional Radiology (IR) procedures.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Regional Scope
  • 1.2.3. Estimates and Forecasts Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
  • 1.4.5. Details of Primary Research
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product Outlook
  • 2.2.2. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Transcatheter Embolization and Occlusion Devices Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Transcatheter Embolization and Occlusion Devices Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political Landscape
    • 3.3.2.2. Technological Landscape
    • 3.3.2.3. Economic Landscape

Chapter 4. Transcatheter Embolization and Occlusion Devices Market: Product Estimates & Trend Analysis

• 4.1. Product Segment Dashboard
• 4.2. Transcatheter Embolization and Occlusion Devices Market: Product Movement Analysis
• 4.3. Global Transcatheter Embolization and Occlusion Devices Market Size & Trend Analysis, By Product, 2018 to 2030 (USD Million)
• 4.4. Coil
  • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Pushable Coils
    • 4.4.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Detachable Coils
    • 4.4.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.5. Non Coil
  • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.5.2. Flow Diverting Devices
    • 4.5.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Embolization Particles
    • 4.5.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.5.4. Liquid Embolics
    • 4.5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.5.5. Other Embolization and Occlusion Devices
    • 4.5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.5.6. Accessories
    • 4.5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. Transcatheter Embolization and Occlusion Devices Market: Regional Estimates & Trend Analysis

• 5.1. Regional Market Dashboard
• 5.2. Regional Market Share Analysis, 2024 & 2030
• 5.3. Transcatheter Embolization and Occlusion Devices Market by Region: Key Takeaways
• 5.4. North America
  • 5.4.1. U.S.
    • 5.4.1.1. Key Country Dynamics
    • 5.4.1.2. Regulatory Framework/ Reimbursement Structure
    • 5.4.1.3. Competitive Scenario
    • 5.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Canada
    • 5.4.2.1. Key Country Dynamics
    • 5.4.2.2. Regulatory Framework/ Reimbursement Structure
    • 5.4.2.3. Competitive Scenario
    • 5.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Mexico
    • 5.4.3.1. Key Country Dynamics
    • 5.4.3.2. Regulatory Framework/ Reimbursement Structure
    • 5.4.3.3. Competitive Scenario
    • 5.4.3.4. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.5. Europe
  • 5.5.1. U.K.
    • 5.5.1.1. Key Country Dynamics
    • 5.5.1.2. Regulatory Framework/ Reimbursement Structure
    • 5.5.1.3. Competitive Scenario
    • 5.5.1.4. U.K. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5.2. Germany
    • 5.5.2.1. Key Country Dynamics
    • 5.5.2.2. Regulatory Framework/ Reimbursement Structure
    • 5.5.2.3. Competitive Scenario
    • 5.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5.3. France
    • 5.5.3.1. Key Country Dynamics
    • 5.5.3.2. Regulatory Framework/ Reimbursement Structure
    • 5.5.3.3. Competitive Scenario
    • 5.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5.4. Italy
    • 5.5.4.1. Key Country Dynamics
    • 5.5.4.2. Regulatory Framework/ Reimbursement Structure
    • 5.5.4.3. Competitive Scenario
    • 5.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5.5. Spain
    • 5.5.5.1. Key Country Dynamics
    • 5.5.5.2. Regulatory Framework/ Reimbursement Structure
    • 5.5.5.3. Competitive Scenario
    • 5.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5.6. Denmark
    • 5.5.6.1. Key Country Dynamics
    • 5.5.6.2. Regulatory Framework/ Reimbursement Structure
    • 5.5.6.3. Competitive Scenario
    • 5.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5.7. Sweden
    • 5.5.7.1. Key Country Dynamics
    • 5.5.7.2. Regulatory Framework/ Reimbursement Structure
    • 5.5.7.3. Competitive Scenario
    • 5.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5.8. Norway
    • 5.5.8.1. Key Country Dynamics
    • 5.5.8.2. Regulatory Framework/ Reimbursement Structure
    • 5.5.8.3. Competitive Scenario
    • 5.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.6. Asia Pacific
  • 5.6.1. China
    • 5.6.1.1. Key Country Dynamics
    • 5.6.1.2. Regulatory Framework/ Reimbursement Structure
    • 5.6.1.3. Competitive Scenario
    • 5.6.1.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6.2. Japan
    • 5.6.2.1. Key Country Dynamics
    • 5.6.2.2. Regulatory Framework/ Reimbursement Structure
    • 5.6.2.3. Competitive Scenario
    • 5.6.2.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6.3. India
    • 5.6.3.1. Key Country Dynamics
    • 5.6.3.2. Regulatory Framework/ Reimbursement Structure
    • 5.6.3.3. Competitive Scenario
    • 5.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6.4. South Korea
    • 5.6.4.1. Key Country Dynamics
    • 5.6.4.2. Regulatory Framework/ Reimbursement Structure
    • 5.6.4.3. Competitive Scenario
    • 5.6.4.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6.5. Australia
    • 5.6.5.1. Key Country Dynamics
    • 5.6.5.2. Regulatory Framework/ Reimbursement Structure
    • 5.6.5.3. Competitive Scenario
    • 5.6.5.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6.6. Thailand
    • 5.6.6.1. Key Country Dynamics
    • 5.6.6.2. Regulatory Framework/ Reimbursement Structure
    • 5.6.6.3. Competitive Scenario
    • 5.6.6.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.7. Latin America
  • 5.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.7.2. Brazil
    • 5.7.2.1. Key Country Dynamics
    • 5.7.2.2. Regulatory Framework/ Reimbursement Structure
    • 5.7.2.3. Competitive Scenario
    • 5.7.2.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.7.3. Argentina
    • 5.7.3.1. Key Country Dynamics
    • 5.7.3.2. Regulatory Framework/ Reimbursement Structure
    • 5.7.3.3. Competitive Scenario
    • 5.7.3.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.8. Middle East and Africa
  • 5.8.1. Middle East and Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.8.2. South Africa
    • 5.8.2.1. Key Country Dynamics
    • 5.8.2.2. Regulatory Framework/ Reimbursement Structure
    • 5.8.2.3. Competitive Scenario
    • 5.8.2.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.8.3. Saudi Arabia
    • 5.8.3.1. Key Country Dynamics
    • 5.8.3.2. Regulatory Framework/ Reimbursement Structure
    • 5.8.3.3. Competitive Scenario
    • 5.8.3.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.8.4. UAE
    • 5.8.4.1. Key Country Dynamics
    • 5.8.4.2. Regulatory Framework/ Reimbursement Structure
    • 5.8.4.3. Competitive Scenario
    • 5.8.4.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.8.5. Kuwait
    • 5.8.5.1. Key Country Dynamics
    • 5.8.5.2. Regulatory Framework/ Reimbursement Structure
    • 5.8.5.3. Competitive Scenario
    • 5.8.5.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments & Impact Analysis, By Key Market Participants
• 6.2. Company/ Competition Categorization
• 6.3. Vendor Landscape
  • 6.3.1. Key Company Heat Map Analysis, 2024
• 6.4. Company Profiles
  • 6.4.1. Boston Scientific Corporation
    • 6.4.1.1. Company Overview
    • 6.4.1.2. Financial Performance
    • 6.4.1.3. Product Benchmarking
    • 6.4.1.4. Strategic Initiatives
  • 6.4.2. Terumo Corporation
    • 6.4.2.1. Company Overview
    • 6.4.2.2. Financial Performance
    • 6.4.2.3. Product Benchmarking
    • 6.4.2.4. Strategic Initiatives
  • 6.4.3. Medtronic
    • 6.4.3.1. Company Overview
    • 6.4.3.2. Financial Performance
    • 6.4.3.3. Product Benchmarking
    • 6.4.3.4. Strategic Initiatives
  • 6.4.4. DePuy Synthes (Johnson & Johnson)
    • 6.4.4.1. Company Overview
    • 6.4.4.2. Financial Performance
    • 6.4.4.3. Product Benchmarking
    • 6.4.4.4. Strategic Initiatives
  • 6.4.5. Stryker
    • 6.4.5.1. Company Overview
    • 6.4.5.2. Financial Performance
    • 6.4.5.3. Product Benchmarking
    • 6.4.5.4. Strategic Initiatives
  • 6.4.6. Cordis
    • 6.4.6.1. Company Overview
    • 6.4.6.2. Financial Performance
    • 6.4.6.3. Product Benchmarking
    • 6.4.6.4. Strategic Initiatives
  • 6.4.7. Abbott
    • 6.4.7.1. Company Overview
    • 6.4.7.2. Financial Performance
    • 6.4.7.3. Product Benchmarking
    • 6.4.7.4. Strategic Initiatives
  • 6.4.8. Pfizer Inc.
    • 6.4.8.1. Company Overview
    • 6.4.8.2. Financial Performance
    • 6.4.8.3. Product Benchmarking
    • 6.4.8.4. Strategic Initiatives
  • 6.4.9. Sirtex SIR-Spheres Pty Ltd.
    • 6.4.9.1. Company Overview
    • 6.4.9.2. Financial Performance
    • 6.4.9.3. Product Benchmarking
    • 6.4.9.4. Strategic Initiatives
  • 6.4.10. Nordion (Canada) Inc.
    • 6.4.10.1. Company Overview
    • 6.4.10.2. Financial Performance
    • 6.4.10.3. Product Benchmarking
    • 6.4.10.4. Strategic Initiatives

관련자료